Spironolactone is associated with reduced white matter lesion progression in patients with hypertension.

Authors :: Yuan Y
Heizhati M
Liu Y
Li N
Source :: European journal of internal medicine [Eur J Intern Med] 2023 Aug; Vol. 114, pp. 146-149. Date of Electronic Publication: 2023 May 15.
Publication Year :: 2023

Subjects :: Humans
Spironolactone therapeutic use
Antihypertensive Agents therapeutic use
Blood Pressure
Mineralocorticoid Receptor Antagonists therapeutic use
White Matter diagnostic imaging
Hypertension drug therapy

Full Text Access

Tools